Global Renal Cell Carcinoma Market – Industry Trends and Forecast to 2029

Market Analysis and Size

RCC has a five-year survival rate of above 70%, according to the National Cancer Institute. Renal cell carcinoma is one of the most rapidly growing solid tumor cancers. The clinical paradigm that governs both renal cell carcinoma comprehension and treatment has changed dramatically during the last few decades.  Renal cell carcinoma is the eighth most prevalent cancer in adults, accounting for between 3% and 4% of all new cancer cases worldwide. Various renowned research institutes have calculated that renal cell carcinoma is the seventh most prevalent cancer in men and the ninth most common cancer in women.

Data Bridge Market Research analyses that the renal cell carcinoma market was valued at USD 635.40 million in 2021 and is expected to reach USD 1005.11 million by 2029, registering a CAGR of 5.90% during the forecast period of 2022 to 2029. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Report Scope and Market Segmentation

Market Definition

Renal cell carcinoma is a cancer that is particularly resistant to systemic therapy in advanced stages. Patient survival has improved as a result of advanced surgical treatments and innovative medications, as well as the extension of clinically stable disease states. Because of the widespread use of abdominal imaging, such as ultrasonography, computed tomography (CT), and magnetic resonance imaging, the proportion of tiny and incidental kidney cancers has increased dramatically (MRI). In metastatic and advanced RCC, the current treatment landscape will move from TKIs and mTOR inhibitors to specialized immuno-oncology medicines such as immune checkpoint inhibitors (ICI), which have shown favourable outcomes on PFS as monotherapy (Opdivo) or combination therapy (Opdivo+Yervoy).

Renal Cell Carcinoma Market Dynamics

Drivers

• Increasing prevalence of cancer

The rising prevalence of cancer is estimated to enhance the renal cell carcinoma market's growth rate. Cancer is the greatest cause of mortality worldwide, according to the World Health Organization (WHO), accounting for approximately 10 million deaths in 2020, or nearly one in every six deaths. Along with this, growing incidences of acquired cystic kidney disease and hepatitis C will increase the risk of renal cell carcinoma that further flourish the market’s growth rate. .  

• Increasing investment for healthcare infrastructure

Another significant factor influencing the growth rate of renal cell carcinoma market is the rising healthcare expenditure which helps in improving its infrastructure. Also, various government organizations aims to improve the healthcare infrastructure by increasing funding and this will further influence the market dynamics.

• Rising geriatric population

One of the primary reasons driving revenue growth in the renal cell carcinoma market is the ageing population. Renal cell carcinoma is also a rare disease with a tiny patient population ranging in age from infants to the elderly. However, the condition is most commonly seen in people aged 60 to 70, indicating a higher risk of incidence.

Furthermore, increasing incidences of obesity and sedentary lifestyle of people such as growing addiction of smoking will expand the renal cell carcinoma market. Additionally, growing government initiatives to spread awareness and presence of favorable reimbursement policies are estimated to enhance the market’s growth rate.

Opportunities

• Increase in the number of research and development activities    

The renal cell carcinoma market's growth is fueled by an increase in the number of research and development activities. This will provide beneficial opportunities for the renal cell carcinoma market growth. Manufacturers of kidney cancer diagnostic systems and healthcare service providers have begun to offer tailored patient care and access to complete end-to-end medical technology products and services for renal cell carcinoma kidney cancer treatment. They are working on product prototyping development and improvement, as well as minimizing operational expenses.

Moreover, increase in the number of emerging markets and rising technological advancement will further provide beneficial opportunities for the renal cell carcinoma market growth during the forecast period.

Restraints/Challenges

On the other hand, high cost associated with the treatment will obstruct the growth rate of market. The dearth of skilled professionals and lack of healthcare infrastructure in developing economies will challenge the renal cell carcinoma market. Additionally, side effects linked with therapies such as heart problems, decreased red blood cell count, fatigue, weight loss, loss of hair, diarrhea, weight loss, decreased lung, kidney, and liver quality and others and lack of awareness among people will act as restrain and further impede the growth rate of market during the forecast period of 2022-2029.

This renal cell carcinoma market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the renal cell carcinoma market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Patient Epidemiology Analysis

Renal cell carcinoma is more common in men than in women (by a factor of 2 or 3), and in those who have smoked in the past. It's also more common in those who have other kinds of kidney problems, and it runs in some families. Renal cell carcinoma is responsible for over 30,000 new instances of kidney cancer in the United States each year.

Renal cell carcinoma market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analyses of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.

COVID-19 Impact on Renal Cell Carcinoma Market

Since its emergence in December 2019, the COVID-19 virus has spread to nearly every country on the planet, prompting the World Health Organization (WHO) to declare it a public health emergency.  In November of 2019, the globe was shocked to learn of the COVID-19 virus.  The COVID-19 pandemic, which was produced by the SARS-CoV-2 virus, had a significant health impact on renal cell carcinoma management and other urology disciplines. The high prevalence of surgery cancellations, including those related to renal cancer, will result in inevitable healthcare overload and, most likely, a deleterious impact on oncological outcomes, particularly in patients with locally advanced and metastatic renal cancer. On the bright side, the renal cell carcinoma market is likely to improve as respective government bodies lifted the enforced lockdown restrictions. Various sectors are anticipated to rebound quickly post COVID-19 pandemic due to the wide number of applications they serve. As a result, the market is projected to stabilize in the future.

Recent Development

• In January 2021, the Food and Drug Administration had announced the approval of combination of nivolumab (Opdivo, Bristol-Myers Squibb Co.) and cabozantinib (Cabometyx, Exelixis) as first-line treatment for patients with advanced renal cell carcinoma (RCC). Nivolumab 240 mg every two weeks (30-minute intravenous infusion) or 480 mg every four weeks (30-minute intravenous infusion) in conjunction with cabozantinib 40 mg orally once day without food until disease progression or unacceptable toxicity is achieved is the suggested dosage.

Global Renal Cell Carcinoma Market Scope

The renal cell carcinoma market is segmented on the basis of treatment, diagnosis, type, dosage forms, route of administration, end-users and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Treatment

• Medication
• Interferon-alfa
• Interleukin-2
• Biologics
• Ablation
• Targeted Therapy
• Axitinib
• Bevacizumab
• Cabozantinib
• Everolimus
• Lenvatinib
• Nivolumab
• Pazopanib
• Sorafenib
• Sunitinib
• Temsirolimus
• Chemotherapy
• Surgery
• Others

Diagnosis

• Urine Tests
• CT scan
• Nephrectomy
• Blood Tests
• Ultrasound
• Biopsy

Type

• Clear Cell RCC
• Papillary RCC
• Chromophobe RCC

Dosage Forms

• Capsule
• Tablets
• Injections
• Others

Route of Administration

• Oral
• Parenteral
• Others

End-Users

• Hospitals
• Specialty Clinics
• Homecare
• Others

Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy
• Others

Renal Cell Carcinoma Market Regional Analysis/Insights

The renal cell carcinoma market is analysed and market size insights and trends are provided by country, treatment, diagnosis, type, dosage forms, route of administration, end-users and distribution channel as referenced above.

The countries covered in the renal cell carcinoma market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America

North America dominates the renal cell carcinoma market because of the presence of key manufacture of the product and established regulatory framework in this region. Additionally, high demand of diseases specific treatment and surging adoption of newer technologies will further propel the market’s growth rate in this region.

Asia-Pacific is expected to grow during the forecast period due to increased government awareness programs and rising healthcare expenditure in this region. Also, growing number of generic drugs manufacturers will further cushion the market’s growth rate in this region.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Competitive Landscape and Renal Cell Carcinoma Market Share Analysis

The renal cell carcinoma market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to renal cell carcinoma market.

Some of the major players operating in the renal cell carcinoma market are:

• F. Hoffmann-La Roche Ltd. (Switzerland)
• Mylan N.V. (U.S.)
• Teva Pharmaceutical Industries Ltd. (Ireland)
• Sanofi (France)
• Pfizer Inc. (U.S.)
• GlaxoSmithKline plc (U.K.)
• Novartis AG (Switzerland)
• Bayer AG (Germany)
• Eli Lilly and Company (U.S.)
• Merck & Co., Inc. (U.S.)
• Allergan (Ireland)
• AstraZeneca (U.K.)
• AbbVie Inc. (U.S.)
• Johnson & Johnson Private Limited (U.S.)
• Cipla Inc. (U.S.)  
• Abbott (U.S.)
• Merck KGaA (Germany)
• LEO Pharma A/S (Denmark)
• Bausch Health Companies Inc. (Canada)
• Sun Pharmaceutical Industries Ltd. (India)
• Aurobindo Pharma (India)
• Lupin (India)
• Hikma Pharmaceuticals PLC (U.K.)
• Fresenius Kabi AG (Germany)
• Amneal Pharmaceuticals LLC. (U.S.)

SKU-53398